TrialThe Lancet. Oncology2015
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.
Harry D Bear et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
66 papers cite itlatest 60 shown
this paperpooled ittrialcites it